David Dai
Stock Analyst at UBS
(2.17)
# 2,838
Out of 5,090 analysts
31
Total ratings
48.15%
Success rate
-3.26%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CATX Perspective Therapeutics | Maintains: Buy | $18 → $7 | $2.40 | +191.67% | 2 | Nov 21, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $14 → $16 | $11.95 | +33.89% | 3 | Nov 14, 2025 | |
| BNTX BioNTech SE | Maintains: Neutral | $115 → $117 | $96.25 | +21.56% | 1 | Nov 6, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $35 → $38 | $20.32 | +87.01% | 3 | Nov 4, 2025 | |
| NUVL Nuvalent | Maintains: Buy | $114 → $132 | $109.60 | +20.44% | 3 | Oct 31, 2025 | |
| MRUS Merus | Downgrades: Neutral | $72 → $97 | $96.14 | +0.89% | 2 | Sep 30, 2025 | |
| TLX Telix Pharmaceuticals | Maintains: Buy | $23 → $20 | $9.85 | +103.05% | 1 | Sep 23, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Buy | $30 → $26 | $18.09 | +43.73% | 2 | Jul 10, 2025 | |
| SMMT Summit Therapeutics | Initiates: Buy | $30 | $18.31 | +63.84% | 1 | Jul 1, 2025 | |
| IOVA Iovance Biotherapeutics | Downgrades: Neutral | $17 → $2 | $2.20 | -9.09% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $24 | $10.59 | +126.63% | 2 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $24 | $38.78 | -38.11% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $69 | $16.51 | +317.93% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $35.87 | +39.39% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $43.30 | +38.57% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $0.53 | +5,141.48% | 1 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $89.47 | -55.29% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $1.37 | +2,819.71% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $1.80 | +2,677.78% | 1 | Nov 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $41 → $52 | $29.90 | +73.91% | 1 | Mar 17, 2020 |
Perspective Therapeutics
Nov 21, 2025
Maintains: Buy
Price Target: $18 → $7
Current: $2.40
Upside: +191.67%
Kura Oncology
Nov 14, 2025
Maintains: Buy
Price Target: $14 → $16
Current: $11.95
Upside: +33.89%
BioNTech SE
Nov 6, 2025
Maintains: Neutral
Price Target: $115 → $117
Current: $96.25
Upside: +21.56%
Syndax Pharmaceuticals
Nov 4, 2025
Maintains: Buy
Price Target: $35 → $38
Current: $20.32
Upside: +87.01%
Nuvalent
Oct 31, 2025
Maintains: Buy
Price Target: $114 → $132
Current: $109.60
Upside: +20.44%
Merus
Sep 30, 2025
Downgrades: Neutral
Price Target: $72 → $97
Current: $96.14
Upside: +0.89%
Telix Pharmaceuticals
Sep 23, 2025
Maintains: Buy
Price Target: $23 → $20
Current: $9.85
Upside: +103.05%
Nurix Therapeutics
Jul 10, 2025
Maintains: Buy
Price Target: $30 → $26
Current: $18.09
Upside: +43.73%
Summit Therapeutics
Jul 1, 2025
Initiates: Buy
Price Target: $30
Current: $18.31
Upside: +63.84%
Iovance Biotherapeutics
May 16, 2025
Downgrades: Neutral
Price Target: $17 → $2
Current: $2.20
Upside: -9.09%
May 12, 2025
Maintains: Buy
Price Target: $30 → $24
Current: $10.59
Upside: +126.63%
Oct 24, 2024
Initiates: Sell
Price Target: $24
Current: $38.78
Upside: -38.11%
Oct 24, 2024
Initiates: Buy
Price Target: $69
Current: $16.51
Upside: +317.93%
Oct 24, 2024
Initiates: Buy
Price Target: $50
Current: $35.87
Upside: +39.39%
Oct 24, 2024
Initiates: Buy
Price Target: $60
Current: $43.30
Upside: +38.57%
Mar 31, 2022
Initiates: Outperform
Price Target: $28
Current: $0.53
Upside: +5,141.48%
Mar 16, 2022
Initiates: Outperform
Price Target: $40
Current: $89.47
Upside: -55.29%
Feb 4, 2022
Initiates: Outperform
Price Target: $40
Current: $1.37
Upside: +2,819.71%
Nov 18, 2021
Initiates: Outperform
Price Target: $50
Current: $1.80
Upside: +2,677.78%
Mar 17, 2020
Upgrades: Outperform
Price Target: $41 → $52
Current: $29.90
Upside: +73.91%